AR092387A1 - Formulaciones de anticuerpo anti receptor de prolactina - Google Patents
Formulaciones de anticuerpo anti receptor de prolactinaInfo
- Publication number
- AR092387A1 AR092387A1 ARP130103084A ARP130103084A AR092387A1 AR 092387 A1 AR092387 A1 AR 092387A1 AR P130103084 A ARP130103084 A AR P130103084A AR P130103084 A ARP130103084 A AR P130103084A AR 092387 A1 AR092387 A1 AR 092387A1
- Authority
- AR
- Argentina
- Prior art keywords
- prolactin
- formulations
- antibody anti
- prlr antibody
- anti receptor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000003946 Prolactin Human genes 0.000 title 1
- 108010057464 Prolactin Proteins 0.000 title 1
- 229940097325 prolactin Drugs 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261695949P | 2012-08-31 | 2012-08-31 | |
| US13/842,906 US8883979B2 (en) | 2012-08-31 | 2013-03-15 | Anti-prolactin receptor antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092387A1 true AR092387A1 (es) | 2015-04-22 |
Family
ID=49162240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103084A AR092387A1 (es) | 2012-08-31 | 2013-08-29 | Formulaciones de anticuerpo anti receptor de prolactina |
| ARP130103100A AR092401A1 (es) | 2012-08-31 | 2013-08-30 | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103100A AR092401A1 (es) | 2012-08-31 | 2013-08-30 | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) |
Country Status (29)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104302664B (zh) | 2012-03-14 | 2021-11-26 | 瑞泽恩制药公司 | 多特异性抗原结合分子及其用途 |
| DK2935331T3 (en) | 2012-12-24 | 2018-06-06 | Abbvie Inc | PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF |
| US20160002342A1 (en) * | 2013-03-15 | 2016-01-07 | Xinghang Ma | Anti-prolactin receptor antibody formulations |
| NZ753995A (en) | 2013-05-30 | 2022-07-01 | Kiniksa Pharmaceuticals Ltd | Oncostatin m receptor antigen binding proteins |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP6784683B2 (ja) * | 2015-02-09 | 2020-11-11 | ユーシービー バイオファルマ エスアールエル | 医薬製剤 |
| NZ737726A (en) | 2015-07-06 | 2023-03-31 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| HUE061985T2 (hu) | 2015-08-19 | 2023-09-28 | Astrazeneca Ab | Stabil IFNAR1-elleni készítmény |
| WO2017057644A1 (ja) * | 2015-09-30 | 2017-04-06 | 持田製薬株式会社 | 高濃度抗体含有液体製剤 |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| CN116327963A (zh) * | 2016-11-21 | 2023-06-27 | 济世-伊沃泰克生物制品有限公司 | 一种眼科制剂及其用途 |
| IL266917B2 (en) | 2016-11-29 | 2023-10-01 | Regeneron Pharma | Anti-human prolactin receptor (prlr) antibody-drug conjugates and use thereof in combination therapy of prlr positive breast cancer |
| TW202228779A (zh) | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| WO2018179138A1 (ja) * | 2017-03-29 | 2018-10-04 | 持田製薬株式会社 | 抗体含有液体製剤 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| WO2018191414A1 (en) | 2017-04-11 | 2018-10-18 | Kiniksa Pharmaceuticals, Ltd. | Stable anti-osmr antibody formulation |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| US12168054B2 (en) | 2017-05-19 | 2024-12-17 | Syndax Pharmaceuticals, Inc. | Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody |
| PE20200481A1 (es) | 2017-07-10 | 2020-03-03 | Bayer Pharma AG | Anticuerpo del receptor de prolactina para la perdida de cabello con patrones masculinos y femeninos |
| EP3713591A1 (en) | 2017-11-20 | 2020-09-30 | Just-Evotec Biologics, Inc. | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| SG11202007363TA (en) | 2018-02-07 | 2020-08-28 | Regeneron Pharma | Methods and compositions for therapeutic protein delivery |
| EP3823594B1 (en) | 2018-07-19 | 2025-02-05 | Ichnos Sciences S.A. | Liquid antibody formulation |
| JP7475335B2 (ja) * | 2018-09-13 | 2024-04-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｃｓｆ－１ｒ抗体製剤 |
| MY209127A (en) * | 2018-10-18 | 2025-06-23 | Merck Sharp & Dohme Llc | Formulations of anti-rsv antibodies and methods of use thereof |
| EP4306128A3 (en) * | 2018-10-30 | 2024-03-27 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| MX2021005394A (es) | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). |
| JOP20210229A1 (ar) | 2019-02-18 | 2023-01-30 | Lilly Co Eli | صيغة جسم مضاد علاجي |
| TW202519263A (zh) * | 2019-03-21 | 2025-05-16 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| WO2021262329A1 (en) * | 2020-06-24 | 2021-12-30 | Alexion Pharmaceuticals, Inc. | Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| JP2025518049A (ja) * | 2022-05-26 | 2025-06-12 | コンピュジェン リミテッド | 抗ｔｉｇｉｔ抗体製剤 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| CA2635352C (en) | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| CA2477857C (en) | 1999-10-04 | 2012-04-10 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| ES2338218T3 (es) | 2001-07-25 | 2010-05-05 | Facet Biotech Corporation | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| SG165158A1 (en) | 2002-05-02 | 2010-10-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| JP4648002B2 (ja) | 2002-06-21 | 2011-03-09 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ｖｉｉ因子ポリペプチドの安定化された固体組成物 |
| CN1751236A (zh) * | 2002-12-16 | 2006-03-22 | 健泰科生物技术公司 | 表达人cd20的转基因小鼠 |
| HUE051878T2 (hu) | 2003-02-10 | 2021-03-29 | Biogen Ma Inc | Immunglobulin készítmény és annak elõállítási módszere |
| AU2004222625A1 (en) | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides |
| CN1761747A (zh) | 2003-03-18 | 2006-04-19 | 诺和诺德医疗保健公司 | 生产含有gla残基的丝氨酸蛋白酶的方法 |
| US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| JP4869064B2 (ja) | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| MX369959B (es) | 2003-05-14 | 2019-11-27 | Immunogen Inc | Composicion de farmaco conjugado. |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| DE602004025100D1 (de) | 2003-05-23 | 2010-03-04 | Novo Nordisk Healthcare Ag | Stabilisierung von proteinen in lösung |
| ES2382157T3 (es) | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
| EP1644030B1 (en) | 2003-07-01 | 2009-10-28 | Novo Nordisk Health Care AG | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| KR101293503B1 (ko) | 2003-08-14 | 2013-08-07 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물 |
| WO2005033143A1 (ja) | 2003-10-01 | 2005-04-14 | Kyowa Hakko Kogyo Co., Ltd. | 抗体の安定化方法及び安定化された溶液状抗体製剤 |
| DE10361599A1 (de) | 2003-12-24 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Flüssigformulierung von Antikörperkonjugaten |
| DE102004022927A1 (de) | 2004-05-10 | 2005-12-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten |
| US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| WO2006014965A2 (en) | 2004-07-27 | 2006-02-09 | Human Genome Sciences, Inc. | Pharmaceutical formulation and process |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008519032A (ja) * | 2004-11-03 | 2008-06-05 | キュラジェン コーポレイション | Ｆｇｆ−２０の調合物、生成方法および使用 |
| DE102005002353A1 (de) * | 2005-01-18 | 2006-07-27 | Abbott Gmbh & Co. Kg | AGER-Rezeptor Multimerisierungs Epitope |
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| WO2007002543A2 (en) * | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| ES2390354T3 (es) | 2005-07-22 | 2012-11-12 | Amgen, Inc | Liofilizados de proteínas concentrados, procedimientos y usos |
| US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| US9084777B2 (en) | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| WO2007092772A2 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
| BRPI0707796A2 (pt) | 2006-02-15 | 2011-05-10 | Imclone Systems Inc | formulaÇço, e, mÉtodo de tratamento |
| TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| CA2932012A1 (en) * | 2006-08-18 | 2008-02-21 | Novartis Ag | Prlr-specific antibody and uses thereof |
| WO2008039761A2 (en) | 2006-09-25 | 2008-04-03 | Medimmune, Llc. | Stabilized antibody formulations and uses thereof |
| MX2009006199A (es) * | 2006-12-11 | 2009-06-22 | Hoffmann La Roche | Formulacion parenteral de anticuerpos abeta. |
| EP2129401B8 (en) | 2006-12-21 | 2020-01-15 | Amgen Inc. | Stable buffered formulations containing polypeptides |
| WO2008081024A1 (en) | 2007-01-03 | 2008-07-10 | Novo Nordisk Health Care Ag | Subcutaneous administration of coagulation factor viia-related popypeptdes |
| MX2009011408A (es) | 2007-05-02 | 2009-11-05 | Hoffmann La Roche | Metodo para estabilizar una proteina. |
| US20100189721A1 (en) | 2007-07-06 | 2010-07-29 | Smithkline Beecham Corporation | Antibody formulations |
| AU2008289225A1 (en) | 2007-08-17 | 2009-02-26 | Amgen Inc. | Formulations of antibodies and Fc-fusion molecules using polycations |
| ES2750254T3 (es) | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
| WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| TW200938221A (en) | 2007-11-30 | 2009-09-16 | Abbott Lab | Protein formulations and methods of making same |
| CN101951950A (zh) * | 2007-12-21 | 2011-01-19 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
| AU2008340429C1 (en) * | 2007-12-21 | 2016-09-08 | F. Hoffmann-La Roche Ag | Antibody formulation |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| JP2011510043A (ja) | 2008-01-23 | 2011-03-31 | ノボ ノルディスク ヘルス ケア アーゲー | 新規血液凝固因子インヒビター |
| AR074357A1 (es) | 2008-11-17 | 2011-01-12 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro |
| CN104398471A (zh) * | 2008-11-28 | 2015-03-11 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| CN104490767A (zh) * | 2009-05-04 | 2015-04-08 | 艾伯维生物技术有限公司 | 人抗TNF-α抗体的稳定高蛋白质浓度制剂 |
| EP2332995A1 (en) | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
-
2013
- 2013-03-15 US US13/842,906 patent/US8883979B2/en active Active
- 2013-08-28 US US14/421,609 patent/US20150252116A1/en not_active Abandoned
- 2013-08-28 WO PCT/US2013/056976 patent/WO2014036076A1/en not_active Ceased
- 2013-08-28 AU AU2013308907A patent/AU2013308907B2/en active Active
- 2013-08-28 CA CA2883097A patent/CA2883097C/en active Active
- 2013-08-28 DK DK13760180.3T patent/DK2890397T3/da active
- 2013-08-28 CN CN201910972236.4A patent/CN111202844A/zh active Pending
- 2013-08-28 KR KR1020157007725A patent/KR102100282B1/ko active Active
- 2013-08-28 CN CN201380053890.6A patent/CN104736175B/zh active Active
- 2013-08-28 LT LTEP13760180.3T patent/LT2890397T/lt unknown
- 2013-08-28 SI SI201331499T patent/SI2890397T1/sl unknown
- 2013-08-28 CN CN201910972059.XA patent/CN111202843A/zh active Pending
- 2013-08-28 IN IN2255DEN2015 patent/IN2015DN02255A/en unknown
- 2013-08-28 MX MX2015002412A patent/MX367691B/es active IP Right Grant
- 2013-08-28 RS RSP20190823 patent/RS59207B1/sr unknown
- 2013-08-28 HU HUE13760180A patent/HUE045494T2/hu unknown
- 2013-08-28 HR HRP20191199TT patent/HRP20191199T1/hr unknown
- 2013-08-28 NZ NZ705178A patent/NZ705178A/en unknown
- 2013-08-28 SG SG11201501225SA patent/SG11201501225SA/en unknown
- 2013-08-28 PL PL13760180T patent/PL2890397T3/pl unknown
- 2013-08-28 EP EP13760180.3A patent/EP2890397B1/en active Active
- 2013-08-28 PT PT13760180T patent/PT2890397T/pt unknown
- 2013-08-28 ES ES13760180T patent/ES2742868T3/es active Active
- 2013-08-28 JP JP2015529978A patent/JP6444871B2/ja active Active
- 2013-08-28 RU RU2015111319A patent/RU2649372C2/ru active
- 2013-08-28 BR BR112015004397-6A patent/BR112015004397B1/pt active IP Right Grant
- 2013-08-29 UY UY0001034994A patent/UY34994A/es not_active Application Discontinuation
- 2013-08-29 TW TW102131090A patent/TW201422235A/zh unknown
- 2013-08-29 AR ARP130103084A patent/AR092387A1/es unknown
- 2013-08-30 AR ARP130103100A patent/AR092401A1/es not_active Application Discontinuation
- 2013-08-30 TW TW102131178A patent/TWI641384B/zh active
- 2013-08-30 TW TW106132855A patent/TWI688404B/zh active
- 2013-08-30 UY UY0001034999A patent/UY34999A/es not_active Application Discontinuation
-
2014
- 2014-09-30 US US14/501,986 patent/US20150093393A1/en not_active Abandoned
-
2015
- 2015-02-17 IL IL237277A patent/IL237277B/en active IP Right Grant
- 2015-02-25 ZA ZA2015/01279A patent/ZA201501279B/en unknown
-
2016
- 2016-09-27 US US15/276,794 patent/US20170008965A1/en not_active Abandoned
-
2019
- 2019-08-16 CY CY20191100880T patent/CY1121990T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092387A1 (es) | Formulaciones de anticuerpo anti receptor de prolactina | |
| AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| HRP20191299T1 (hr) | Formulacije protutijela | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| MX377841B (es) | Formulación liofilizada de conjugado de anticuerpo-fármaco. | |
| PE20170780A1 (es) | Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| HRP20191827T1 (hr) | Formulacija protutijela | |
| BR112018067792A2 (pt) | preparação contendo o anticorpo | |
| BR112012018023A2 (pt) | formulações líquidas que contêm anticorpo estabilizado. | |
| PH12014502460A1 (en) | Lyophilised and aqueos anti-cd40 antibody formulations | |
| MX2020000333A (es) | Formulaciones de conjugado anticuerpo anti-egfr-farmaco. | |
| FI3769781T3 (fi) | Stabiili anti-ifnar1-formulaatio | |
| AR090272A1 (es) | FORMULACION DE ANTICUERPOS Ab | |
| BR112016026811A2 (pt) | formulação de anticorpo | |
| JP2018523676A5 (cg-RX-API-DMAC7.html) | ||
| CL2015002330A1 (es) | Análogo de insulina novedoso y su uso. | |
| PH12014501628B1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| NZ601114A (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies | |
| UA113172C2 (uk) | Стійкий рідкий препарат етанерцепту | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| HRP20191137T1 (hr) | Formulacije otopina konstruiranih anti-il-23p19 antitijela | |
| TW201613557A (en) | Stable aqueous recombinant protein formulations | |
| BR112017013269A2 (pt) | ?composição farmacêutica líquida? | |
| NZ741483A (en) | Antibody and protein formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |